NCT05766839

Patiromer for Treatment of Hyperkalaemia in Children Under 12 Years of Age

A 2-Part, Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children Under 12 Years of Age With Hyperkalaemia (EMERALD2)

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 32 (estimated)
• Sponsor: Vifor Pharma, Inc. · Industry
• Sex: All
• Age: 0 Years – 11 Years
• Healthy volunteers: Not accepted

Summary

A study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer in children under 12 years of age with hyperkalaemia.

Conditions

• Hyperkalemia

Interventions

Type	Name	Description
DRUG	Patiromer	Patiromer will be given once daily; In Cohort 3, depending on the dose and the study participant's age, the total daily dose might be split

Timeline

• Start date: 2025-04-06
• Primary completion: 2029-12-01
• Completion: 2030-12-01
• First posted: 2023-03-13
• Last updated: 2026-03-13

Locations

37 sites across 15 countries: United States, Australia, Belgium, Finland, France, Greece, Israel, Italy, Norway, Poland, Portugal, Qatar, Romania, Saudi Arabia, United Arab Emirates

Regulatory

• FDA-regulated drug study